Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Stem Cell-Based Therapies for Multiple Sclerosis: Current Perspectives.

Cuascut FX, Hutton GJ.

Biomedicines. 2019 Mar 30;7(2). pii: E26. doi: 10.3390/biomedicines7020026. Review.

2.

Advanced neuroimaging in Balo's concentric sclerosis: MRI, MRS, DTI, and ASL perfusion imaging over 1 year.

Yeo CJJ, Hutton GJ, Fung SH.

Radiol Case Rep. 2018 Jun 1;13(5):1030-1035. doi: 10.1016/j.radcr.2018.04.010. eCollection 2018 Oct.

3.

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.

Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stuve O, Arnold DL, Wener MH, Georges GE, Wundes A, Kraft GH, Bowen JD.

Neurology. 2017 Feb 28;88(9):842-852. doi: 10.1212/WNL.0000000000003660. Epub 2017 Feb 1.

4.

Newly diagnosed ganglioglioma in an adult patient with multiple sclerosis.

Mandel JJ, Goethe EA, Patel AJ, Heck K, Hutton GJ.

J Neurol Sci. 2016 Oct 15;369:51-52. doi: 10.1016/j.jns.2016.07.024. Epub 2016 Jul 12. No abstract available.

PMID:
27653865
5.

Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial.

Yapundich R, Applebee A, Bethoux F, Goldman MD, Hutton GJ, Mass M, Pardo G, Klingler M, Henney HR 3rd, Blight AR, Carrazana EJ.

Int J MS Care. 2015 May-Jun;17(3):138-45. doi: 10.7224/1537-2073.2014-040.

6.

Abnormal rhythms in patients without known cardiac disease after a first dose of fingolimod.

Schurmann P, Basra S, Awar OG, Aguilar D, Basant A, Dragan E, Hutton GJ, Birnbaum Y.

Mult Scler Relat Disord. 2014 May;3(3):408-12. doi: 10.1016/j.msard.2013.11.001. Epub 2013 Nov 28.

PMID:
25876482
7.

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.

Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O, Arnold DL, Spychala ME, McConville KC, Harris KM, Phippard D, Georges GE, Wundes A, Kraft GH, Bowen JD.

JAMA Neurol. 2015 Feb;72(2):159-69. doi: 10.1001/jamaneurol.2014.3780.

8.

A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper.

Saccardi R, Freedman MS, Sormani MP, Atkins H, Farge D, Griffith LM, Kraft G, Mancardi GL, Nash R, Pasquini M, Martin R, Muraro PA; European Blood and Marrow Transplantation Group; Center for International Blood and Marrow Research; HSCT in MS International Study Group.

Mult Scler. 2012 Jun;18(6):825-34. doi: 10.1177/1352458512438454. Epub 2012 Mar 1.

9.

IFN-β induces the proliferation of CD4+CD25+Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis.

Chen M, Chen G, Deng S, Liu X, Hutton GJ, Hong J.

J Neuroimmunol. 2012 Jan 18;242(1-2):39-46. doi: 10.1016/j.jneuroim.2011.10.014. Epub 2011 Nov 21.

PMID:
22112394
10.

The role of postpartum intravenous corticosteroids in the prevention of relapses in multiple sclerosis.

Avila-Ornelas J, Avila M, Stosic M, Robles L, Prieto PG, Hutton GJ, Rivera VM.

Int J MS Care. 2011 Summer;13(2):91-3. doi: 10.7224/1537-2073-13.2.91.

11.

Functional brain network changes associated with maintenance of cognitive function in multiple sclerosis.

Helekar SA, Shin JC, Mattson BJ, Bartley K, Stosic M, Saldana-King T, Montague PR, Hutton GJ.

Front Hum Neurosci. 2010 Nov 22;4:219. doi: 10.3389/fnhum.2010.00219. eCollection 2010.

12.

Regulatory effects of interferon-β on osteopontin and interleukin-17 expression in multiple sclerosis.

Hong J, Hutton GJ.

J Interferon Cytokine Res. 2010 Oct;30(10):751-7. doi: 10.1089/jir.2010.0082. Review.

PMID:
20874252
13.

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH; OLYMPUS trial group.

Ann Neurol. 2009 Oct;66(4):460-71. doi: 10.1002/ana.21867.

PMID:
19847908
14.

Pneumocephalus after an epidural steroid injection.

Hutton GJ, Avila M, Suarez GA.

Clin Neurol Neurosurg. 2009 Apr;111(3):309-10. doi: 10.1016/j.clineuro.2008.10.009. Epub 2008 Nov 25. No abstract available.

PMID:
19036497
15.

Heart-shaped lesion secondary to neurosarcoidosis.

Suárez Zambrano GA, Hutton GJ.

Arch Neurol. 2008 Oct;65(10):1388-9. doi: 10.1001/archneur.65.10.1388. No abstract available.

PMID:
18852359
16.

Spectrum of pediatric neuromyelitis optica.

Lotze TE, Northrop JL, Hutton GJ, Ross B, Schiffman JS, Hunter JV.

Pediatrics. 2008 Nov;122(5):e1039-47. doi: 10.1542/peds.2007-2758. Epub 2008 Oct 6.

PMID:
18838462
17.

Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up.

Optic Neuritis Study Group.

Arch Neurol. 2008 Jun;65(6):727-32. doi: 10.1001/archneur.65.6.727.

18.

Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial.

Optic Neuritis Study Group.

Ophthalmology. 2008 Jun;115(6):1079-1082.e5. Epub 2007 Nov 5.

PMID:
17976727
19.

Autologous HSCT for advanced MS: is the glass half-empty or really half-full?

Nash RA, Stuve O, Bowen JD, Frohman EM, Griffith LM, Hutton GJ, Kraft GH, Popat U, Racke MK, Muraro PA.

Brain. 2008 Feb;131(Pt 2):e89; author reply e90. Epub 2007 Sep 30. No abstract available.

PMID:
17908695
20.

The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis.

Bakshi R, Hutton GJ, Miller JR, Radue EW.

Neurology. 2004 Dec 14;63(11 Suppl 5):S3-11. Review.

PMID:
15596734

Supplemental Content

Loading ...
Support Center